DUBLIN--(BUSINESS WIRE)--Research and Markets(http://www.researchandmarkets.com/research/8db050/panic_disorders) has announced the addition of Global Markets Direct's new report "Panic Disorders - Pipeline Review, H2 2011" to their offering.
Global Markets Direct's, 'Panic Disorders - Pipeline Review, H2 2011', provides an overview of the Panic Disorders therapeutic pipeline. This report provides information on the therapeutic development for Panic Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Panic Disorders. 'Panic Disorders - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Scope
- A review of the Panic Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Panic Disorders pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
Key Topics Covered:
- Introduction
- Global Markets Direct Report Coverage
- Panic Disorders Overview
- Therapeutics Development
- An Overview of Pipeline Products for Panic Disorders
- Panic Disorders Therapeutics under Development by Companies
- Panic Disorders Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Pre-Clinical Stage Products
- Comparative Analysis
- Panic Disorders Therapeutics - Products under Development by Companies
- Panic Disorders Therapeutics - Products under Investigation by Universities/Institutes
- Companies Involved in Panic Disorders Therapeutics Development
- IntelGenx Technologies Corp.
- Abiogen Pharma S.p.A.
- Panic Disorders - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- ABIO 08/01 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- INT0015 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- D-Cycloserine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Clonazepam + Sertraline - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Panic Disorders Therapeutics - Discontinued Products
- Panic Disorders - Featured News
- Mar 30, 2011: Bionomics Successfully Completes Two Phase Ib Clinical Trials Of BNC210
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
For more information visit http://www.researchandmarkets.com/research/8db050/panic_disorders